Entering text into the input field will update the search result below

Cronos: Cannabis Unicorn With First-Ever Nasdaq Listing

Cornerstone Investments profile picture
Cornerstone Investments


  • Cronos saw share price jump 37% this week after Nasdaq listing.
  • Market reached $1.9 billion, closing in on MedReleaf and Aphria.
  • Early-stage cannabis company with only $1 million in quarterly revenue, raising concerns over overheated valuation amid Nasdaq listing.

We are excited to introduce our Discover Cannabis series. Every week we will introduce a new cannabis company to our readers. Besides our Weekly Cannabis Report where we provide a weekly review p of key developments and trading updates in the cannabis space, we have been asked by readers to expand our coverage outside the large caps. Although we have repeatedly shared our views that small producers are inherently risky in the cannabis industry given that distribution channels are controlled by the government and market is likely to be oversupplied post-legalization, we still believe in the value of offering a broader coverage to our readers. Cannabis will be a large and diversified market with abundant opportunities for many successful ventures. Besides the large-cap names, we think investors could be well-served to learn about other up-and-coming players. With that, we are excited to start with Cronos Group this week after it made headlines last week.

Situation Overview

Cronos Group (NASDAQ:CRON) shocked the cannabis sector by becoming the first Canadian cannabis company to be listed on the Nasdaq. Cronos started trading on the Nasdaq under "CRON" on Tuesday and ended the week 37% higher. With $1.9 billion in market capitalization, Cronos has become top 5 cannabis companies in Canada by market capitalization. Another giant has been born in the cannabis industry and we think investors should take notice of it.

Cronos, Weed, Cannabis, Marijuana


Nasdaq Listing

Cronos' listing on the Nasdaq was a first for Canadian cannabis company. Cronos was able to supersede larger players such as Canopy (TWMJF), Aurora (ACBFF), Aphria (APHQF), and MedReleaf (OTCPK:MEDFF) to list on the Nasdaq first and the benefit has been evident in the share price. Cronos ended the week with its share price up 37% lifting its market capitalization to $1.9 billion. The listing has

This article was written by

Cornerstone Investments profile picture
We are your best guide to cannabis investing. Read our 2021 Cannabis Sector Outlook here. We also provide in-depth industry analysis and coverage of 70+ cannabis stocks to help you get started.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (66)

CRON getting cheaper as the trade spat with China continues. Lets see how low it goes before bottoming out. Thinking it could still drop some more if the bs in D.C. continues. On my watch list, gets any cheaper & I'll seriously think about accumulating a few shrs & start a long term position.
mykie profile picture
Great conversation on Medmen/Cronos and how regulation plays a part in their lives.

Very elucidating and I've gained valuable knowledge from you two guys, (Gregoriou and Cornerstone.)

Thanks much,
Long Cronos and will get longer on next dip
author what do u make of the medmen news out today? medmen has been looking to ipo thru a Canadian company, does this mean it's probably going to end up being Cronos?
Cornerstone Investments profile picture
They formed a JV with Cronos so it is unlikely they will expand in Canada outside of the JV. The listing is more to provide avenues for Canadian investors to access the stocks. The listing through a shell company is a common practice here and fundamentally different from Cronos listing on Nasdaq. Nasdaq to Cronos means access to the massive American investor base. Medmen listing on Canada's CSE will result in limited liquidity as many investors only invest on the TSX.
thanks, im in agreement. i dont see how they can list through another shell company in canada.

One thing i think you're missing though is that Medmen has publicly stated that they want to ipo through a canadian shell so that they can avoid the confusion of US regulations at this time. I don't agree that investors are confining themselves to TSX.
Some companies like Aurora, and namaste technologies built up massive market caps despite their CSE listing, and many americans were buying into them.
my admittedly novice prediction: Medmen doesn't IPO but eventually just merges into Cronos and cronos adds 75 million shares or so.
medmen's estimated market cap is to be north of a billion stateside, and cronos is about 2 billion give or take so the merger seems viable for both sides simply by adding 75 million outstanding shares. This will also be necessary for cronos and medmen if they want to take Canopy head on. Cronos is also the ideal merge partner because they're already on the nasdaq, giving them full access to US investment.

Long story short I think you have to be long Cronos now more than ever. Maybe not a full position, but at least initiate something. The prospects look very bright for both companies based on this news.
Cornerstone Investments profile picture
Cronos can list on the Nasdaq because it only does business in Canada. The reason why MedMen can't list on Nasdaq is because cannabis is still illegal on federal level. So Cronos cannot acquire MedMen as they would lose Nasdaq listing.
Leonardo_Pisano profile picture
@CI: thanks for the article.
I don't like that the management team doesn't seem to have people who know the cannabis business, at least from a plant growing/production viewpoint. So I pass this one.

FWIW, there is another cannabis company listed on the NASDAQ, but admittedly not a pure grower. I am long Innovative Industrial Properties, Inc. (IIPR) which is in the sale-and-lease-back business for cannabis producers.
mykie profile picture
Hi Beery1,

Have you figured out which dilutions are overdone and which are done such that they can be digested successfully at some later date and produce a more reasonable P/E ratio?

mykie profile picture
I sold some Cron yesterday at $12.51 with the intent of taking some profits and buying back later.

I can't see how the present valuations can hold and at some point (as they did on February 5th) they'll come back to earth. I don't think this will be a straight line for any of the MJ stocks and this one got a bump only due to listing on NASDAQ. Besides, when did stocks start going up in a straight line? And these are not AMZN like companies, with profits being plowed back into cap ex, these are examples of more debt being piled on, more dilution and all on spec which means one straw too many and down they come.

As the others list up to NASDAQ and get their price bumps, I'll sell into those catalysts also, looking to buy back at a later date with most.

This is just my take and everyone should do what they think is right for them. I'm not leaving the field, just pruning the buds and looking for more buds to grow back in the future.
Beery1 profile picture
Glad for your last sentence, cuz the biggest catalysts are still ahead.
I wonder how HIGH it will go?
what is a reasonable entry point for a newbie? looking to buy 500 shares.
iamkk77 $5-$6 ??
Long Horns profile picture
If you're confident in the weed sector, buy at around ~$7.50 or $8.00 - the point at which I'm guessing it will drop down and intersect with the 50 day MA. Just my 2 cents.
Personally, I'm planning to invest directly in both Canopy and Aurora before they are listed on the US exchanges - but after I've heard some additional reassurance on the Canadian political front.
oatsuzn profile picture
That would be a great price but highly unlikely unfortunately. Their recent $40+mill raise was done by selling shares around $7 - 8.
Nick Cox profile picture
I agree the price is very frothy,this might be a Buy but only after the price comes down somewhat.
I'm rather intrgued about their Australian operations, especially about exporting tp S-E Asia.Don't hold your breath on that one.In general,S-E Asian countries have the strongest anti-cannabis laws of any area of the world.
Dan in Mexico profile picture
I'm going to provide a link to a Bloomberg story that isn't particularly relevant to this article, but IS most relevant to the medical marijuana issue.


mykie profile picture
Dan in Mexico,

Muchas gracias for the article. Great read, informative and intriguing.

Isn't it counter intuitive that we have the highest drug cost per capita in the USA, that marijuana is an inexpensive replacement for opiods and yet we can't get it into the use cycle? I find that astounding though, probably it is just one of the astounding and dumb things that cause our health care system to be so out of touch.

PS I also find it surprising that our business man President doesn't do something about our falling behind in what will be an enormous business and hence, don't think he will stand for that for long. Once he comes around, we'll have a nice catalyst for any MJ stocks we own.
I own 15 MJ stocks, Cronos being one along with the big 4 etc....
Dan in Mexico profile picture

De nada. One of the other benefits of living in Mexico is that the cost of Rx meds is much lower than in the states. Sometimes though we can't get the newest med for awhile. My wife and I are lucky that all of the meds that we require are generic.

When I still lived in the US my health care insurance wouldn't cover acupuncture, which cost much less than a doctor's office visit. Cannabis isn't covered as you mentioned. The US has real problems thinking "outside the box". If there was ever an issue where politics gets in the way of progress, this must surely be the poster child for it.

The federal government blindness on cannabis is truly astounding. That will change though, with 29 states having legally approved medical marijuana, those states federal representatives and senators will change the law. In my reading the best guesses by knowledgeable people is in 3 to 5 years. In the meantime the US is ceding the medical research to foreigners, along with the possible patentable medicines to be derived.

The US has and will always have cannabis businesses, however, the Canadian cannabis businesses are busy establishing sales and distribution channels, both across Canada and internationally. They are also growing domestic cannabis medical clinics! Speaking about outside the box thinking...

I only own one cannabis stock, Canopy, which is 5% of my portfolio. When the US comes up with a cannabis ETF without tobacco companies, I'll buy it. I can't buy the Canadian ETF at TD Ameritrade. At 70, I'm cutting way back on having to follow individual stocks. I want to make it easy for my daughter who will eventually manage my portfolio.

Ten un buen día.

6 MARCH 2018
• Tissue culture to be imported from partners Aurora Cannabis & Anandia Labs
• Broadens Cann’s bank of genetics & cultivation capability
• Four cannabis oil products developed by Aurora Cannabis to be imported for use
by Australian patients
6 March 2018 – Cann Group Limited (ASX: CAN) has been granted import permits by the
drug control section of the Therapeutic Goods Administration (TGA) that enables the
company to commence the import of genetics and cannabis oils from its Canadian partners.
The receipt of the genetics import permits will see Cann begin importing tissue culture from
Aurora Cannabis and Anandia Labs, which will be used to develop mother plants for Cann’s
cultivation activities.
The importation of these genetics will allow Cann to establish a bank of various genetics,
therefore facilitating research into the suitability of each genetic strain for certain
therapeutic applications.
In addition, by fostering a plant breeding program Cann will establish surety around the
supply of material moving forward and broaden this supply beyond locally available gene
Cann Group has immediately commenced the process to import the tissue culture, which
will be received in the coming weeks pending a quarantine screening process conducted by
the Department of Agriculture and Water Resources.
The import permits for cannabis oil will allow Cann to bring four products developed by
Aurora Cannabis to Australia, which will be made available to medical practitioners seeking
to provide medicinal cannabis to patients under the Special Access Scheme or Authorised
Prescriber Scheme.
In respect of both sets of permits, the corresponding export permits from Health Canada
have also been secured.
Cann Group CEO Peter Crock said working closely with quality Canadian partners enables
the Company to more quickly advance its own development.
“With these genetics we will broaden our genetic base and improve our ability to cultivate
various strains of medicinal cannabis,” he said

“In addition to this, we are serious about providing access to product for Australian patients
as quickly and easily as is possible, and the importation of oils fast-tracks this while we
develop our own capabilities and products within Australia.”
some of Canadian growers have usa subsidiary activity.
CRON will also benefit from as a safe haven investment whenever the market goes up in smoke.
Cornerstone Investments profile picture
Interesting point. We too have noticed the lack of correlation between cannabis stocks and the general equity market in recent months. Hoping to write up a piece on this at some point.
Long Horns profile picture
On the other hand, I'm wondering if this might cause some of the Canadian weed stocks to have a bit more sensitivity than before to US market fluctuations (noticing the drops in prices across the sector today..)?
In your article, you mentioned they lack distribution, then you stated they have exclusive contract with 12000 pharma industry in Germany (Phohl) that seems like excellent distribution to me! One of the largest legal countries in the world...
Cornerstone Investments profile picture
Was referring their lack of involvement so far in domestic Canadian market, which will be largest near-term opportunity
Serious question as someone still new to buying ADRs - what happens to the OTC securities when a company lists on NASDAQ?
JCurse profile picture
I am also curious about this. Will the OTC shares get automatically converted to the new NASDAQ one?
yes. you don't have to do anything. they just change over. that's been my experience anyway.
oatsuzn profile picture
All my PRMCF shares that I've been holding since 2016 transferred over fine. Went to sleep as PRMCF on the OTC, woke up as CRON on the Naz.
Just wait till the Canada's big 4 hit Nasdaq. Go Canada Go!
They've been turning a profit before the others have.
newfruit profile picture
I recently bought shares of Cronos, they're one of the quality LPs I missed on the way up. Their management has navigated international trade deals and licensing, not to mention Nasdaq listing... they are in full compliance with applicable laws and stand to benefit greatly as this industry expands.
Cornerstone Investments profile picture
Cronos has done shareholder well for sure!
Moats and Income profile picture
Definitely got a boost to its share price - like the January boost for the TSX cannabis stocks...

Also have to consider Cronos has always been a significant part of all the Cannabis Funds...so, they are not a nobody...probably a #6 in the industry and worth owning - but not overweight
Cornerstone Investments profile picture
Yep market of $2 billion is very heavy given the current production plan. Would not overweight at this point given the inflated price.
NeoHippie87 profile picture
I really like your piece. I would like to add that some of their share price can be attributed to their investments in other medical cannabis companies. So there's that.
Cornerstone Investments profile picture
Thanks, agreed.
Bay Area Kid profile picture
Wow, they are pretty bad at growing pot. At less than 140 grams/sq ft, they are below the industry average. All these companies building these horribly inefficient growing operations, when a company like Abcann Global is doubling their yields.
06 Mar. 2018
Quality > Quantity
Bay Area Kid profile picture
Abcann Global is also the industry leader in consistency and purity. They grow the highest quality marijuana at the highest yields. Trying to figure out why they haven't been bought out for their tech
oatsuzn profile picture
LOL read filings. ABcann was one of Cronos' minority holdings lol. Their management routinely share ideas and workflow. Cronos still owns millions of equity in ABcann...again, read filings!!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.